References 1 WHO: Leishmaniasis: magnitude of the problem World

References 1. WHO: Leishmaniasis: magnitude of the problem. World Health Org 2013. [http://​www.​who.​int/​leishmaniasis/​burden/​magnitude/​burden_​magnitude/​en/​]URL 2. Fernández-Guerrero ML, Robles P, Rivas P, Mójer F, Muñíz G, Górgolas M: Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 2004, 90:11–16.PubMedCrossRef 3. Carnaúba-Jr

D, Konishi CT, Petri V, Martinez ICP, Shimizu L, Pereira-Chioccola VL: Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania ( Leishmania ) infantum chagasi DMXAA : a case report. Int J Infect Dis 2009, 13:504–507.CrossRef 4. Barral A, Pedral-Sampaio D, Grimaldi Júnior G, Momen H, McMahon-Pratt D, Ribeiro De Jesus A, Almeida R, Badaro R, Barral-Netto M, Carvalho EM, Johnson Júnior WD: Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am selleck compound J Trop Med Hyg 1991, 44:536–546.PubMed 5. Oliveira JPC, Fernandes F, Cruz AK, Trombela V, Monteiro E, Camargo AA, Barral A, Oliveira CI: Genetic diversity of Leishmania amazonensis strains isolated in northeastern Brazil as revealed by DNA sequencing, PCR-based analyses and molecular karyotyping. Kinetoplastid Biol

Dis 2007. doi:10.1186/1475–9292–6-5CrossRef 6. Croft SL, Coombs GH: Leishmaniasis – current chemotherapy and recent advances in the search for novel drugs. Trends

Parasitol 2003, 19:502–508.PubMedCrossRef 7. Tiuman TS, Santos AO, Ueda-Nakamura T, Dias Filho BP, Nakamura CV: Recent advances in leishmaniasis treatment. Int J Infect Dis 2011, 15:e525-e532.PubMedCrossRef 8. Croft SL, Sundar S, Fairlamb AH: Drug resistance in leishmaniasis. Clin Microbiol Rev 2006, 19:111–126.PubMedCentralPubMedCrossRef 9. Natera S, Machuca C, Padrón-Nieves M, Romero A, Lck Díaz E, Ponte-Sucre A: Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents 2007, 29:637–642.PubMedCrossRef 10. Tiuman TS, Ueda-Nakamura T, Cortez DAG, Dias Filho BP, Morgado-Díaz JA, De Souza W, Nakamura CV: Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium . Antimicrob Agents Chemother 2005, 49:176–182.PubMedCentralPubMedCrossRef 11. Tiuman TS, Ueda-Nakamura T, Dias-Filho BP, Cortez DAG, Morgado-Díaz JA, Nakamura CV: Morphologic and ultrastructural alterations in Leishmania amazonensis induced by 4a,5β-epoxy-germacra-1(10),11(13)-dien-12,6a-olide. Acta Protozool 2007, 46:349–355. 12. Linsinger G, Wilhelm S, Wagner H, Häcker G: Uncouplers of oxidative phosphorylation can enhance a Fas death signal. Mol Cell Biol 1999, 19:3299–3311.PubMedCentralPubMed 13.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>